ClinicalTrials.gg

Pneumonia, Bacterial clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 153 studies for Pneumonia, Bacterial across more than 10 countries. 27 are recruiting or about to start. 91 of them are mainly about Pneumonia, Bacterial (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-27. Counting its 2 narrower conditions too, such as Pneumonia, Pneumococcal: 214 studies, 32 open.

Status

Completed
94
Recruiting
18
Status unknown
12
Terminated
9
Not yet recruiting
8
Active, not recruiting
6

Phase

Phase 3
38
Phase 2
26
Phase 1
12
Phase 4
9

Where

United States
50
France
22
Spain
14
Germany
12
Taiwan
12
Hungary
10

Who develops what

Add Pneumonia, Bacterial to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 11 programs from 10 companies, 10 with this as their studies’ main aim; 5 with a live phase 3 study; 2 primary completions in the next 12 months. Compare Beijing Aosaikang Pharmaceutical, GlaxoSmithKline and Jiangsu HengRui Medicine here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
avibactam, ceftazidime drug combinationRecent, repeated
Evidence
  • NCT07885891 · Wockhardt · Phase 3 · live · comparator · “Ceftazidime-avibactam with or without Colistin” · registered Sep 2026
  • NCT07634198 · Nanjing Yoko Biomedical Co., Ltd. · Phase 3 · live · comparator · “Ceftazidime-avibactam Injection” · registered Apr 2026
  • NCT07327619 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Ceftazidime-avibactam” · registered Dec 2025
Pfizer90% of its industry studies33 studies
MeropenemRecent, repeated
Evidence
  • NCT07512596 · Sino Biopharmaceutical Limited · Phase 2 · live · background · “Meropenem for injection” · registered Mar 2026
  • NCT06841731 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 · comparator · “Meropenem” · registered Feb 2025
  • NCT06168734 · Venatorx Pharmaceuticals, Inc. · Phase 3 · comparator · “Meropenem” · registered Dec 2023
Pfizer40% of its industry studiesUS: off-patent, 8 generics marketed33 studies
ColistinRecent, repeated
Evidence
  • NCT07885891 · Wockhardt · Phase 3 · live · comparator · “Ceftazidime-avibactam with or without Colistin” · registered Sep 2026
  • NCT07326540 · BioVersys SAS · Phase 3 · live · comparator · “Colistin” · registered Jan 2026
—22 studies
ClarithromycinRecent, repeated
Evidence
  • NCT06804096 · Dr. Md. Alimur Reza · Phase 4 · comparator · “Clarithromycin 500 mg” · registered Jan 2025
  • NCT05417997 · raas nutritionals llc · Phase 3 · background · “Ceftriaxone/ Clarithromycin” · registered May 2022
  • NCT00621504 · AbbVie · Phase 3 · background · “Clarithromycin” · registered Feb 2008
Abbott13% of its industry studies22 studies

16 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
BV100☆ Track1 live phase-3 study: NCT07326540BioVersys SAS
Polymyxin B☆ Track1 live phase-3 study: NCT07326540BioVersys SAS
cefepime-zidebactam☆ Track1 live phase-3 study: NCT07885891Wockhardt
YK-1169☆ Track1 live phase-3 study: NCT07634198Nanjing Yoko Biomedical Co., Ltd.
pralurbactam☆ Track1 live phase-3 study: NCT07327619Qilu Pharmaceutical Co., Ltd.

The 5 in phase 3 with the nearest primary completion, of 11 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Jul 2027 est.TQD3524 · Sino Biopharmaceutical Limited · Phase 2 main aimadded to MeropenemNCT07512596 Study on the Safety and Efficacy of Polymyxin E2 Methanesulfonate for Injection in the Treatment of Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacteria — primary endpoint: The proportion of subjects who achieved clinical cure · 48 enrolled
  • 20 Oct 2027 est.ASK0912 · Beijing Aosaikang Pharmaceutical Co., Ltd. · Phase 2 main aim+ ASK0912, ASK0912 for Injection vs Polymyxin BNCT07759934 ASK0912 Versus Polymyxin B for Injection in Adults With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia — primary endpoint: Percentage of Participants Achieving Clinical Cure at Test of Cure (TOC) Visit in the Modified Intent to Treat (MITT) Population · 60 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Pneumonia, Bacterial studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Beta-lactamase inhibitors 3

Coming up

11studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest

Who these studies take

Of the 18 Pneumonia, Bacterial studies recruiting now, 12 (67%) set no upper age limit and 2 (11%) stop at 75 or younger. 2 (11%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (6%) take healthy volunteers.

Recruiting studies that take each age, of 18
AgeWomenMen
101 (6%)1 (6%)
1815 (83%)15 (83%)
3016 (89%)16 (89%)
4016 (89%)16 (89%)
5016 (89%)16 (89%)
6516 (89%)16 (89%)
7516 (89%)16 (89%)
8514 (78%)14 (78%)

Across all 153 studies, recruiting or not: 23% stop at 75 or younger and 18% at 65; 21% take children; 1% are for women only and 0% for men only; 11% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Pneumonia, Bacterial studies take

Of 15 phase 3 interventional studies under Pneumonia, Bacterial, half reached primary completion within 25 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 325 mo15–45 · 15 studies——
Interventional, no phase24 mo17–39 · 19 studies——
Observational24 mo14–49 · 22 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 153. Browse all 153 → or search them.